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Abstract
Volatile anesthetics are known to have immunomodulatory effects in conditions of organ injury. A recent study in an
experimental sepsis model has shown remarkably improved survival when mice were exposed to volatile anesthetics. In the
present study, we show that hexafluoroisopropanol – a water-soluble primary sevoflurane metabolite – has beneficial
effects on the overall survival in a murine model of cecal ligation and puncture. Seven-day survival as well as tissue damage
markers including transaminases and high mobility group box protein-1 were assessed as measures of end organ damage.
In animals undergoing cecal ligation and puncture procedure hexafluoroisopropanol conditioning - but not late
postconditioning 24 hours after sepsis induction - significantly increased survival rate (17% vs. 77%, p = 0.037) and
attenuated secretion of organ damage markers. This study shows survival benefits by administration of the metabolite of a
volatile anesthetic. If successfully translated, hexafluoroisopropanol might offer interesting therapeutic opportunities in the
future treatment of abdominal sepsis.
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Introduction
Volatile anesthetics have been shown to positively affect
outcome after ischemia reperfusion injuries in both clinical and
basic research studies [1,2,3]. Most recently, it has been
demonstrated in an experimental sepsis model that conditioning
with desflurane or sevoflurane and post-conditioning with
sevoflurane improves survival in murine septic peritonitis [4].
We now found similar effects by intravenous administration of
hexafluoroisopropanol (HFIP, water-soluble trifluorinated small
molecule, (CF3)2CHOH), a primary metabolite of sevoflurane,
instead. Trifluorinated small molecules have previously been
shown to exert immunomodulatory effects similar to volatile
anesthetics in an in vitro model of lipopolysaccharide (LPS)-
induced cell injury [5]. However, only successful translation into
an in vivo model allows first evaluation of the significance of these
results. In the present study, we investigated in a state-of-the-art
model of murine sepsis with intra-abdominal focus (peritonitis)
whether HFIP application improves overall survival of septic
animals. Tissue damage markers including blood urea, transam-
inases and high mobility group box protein-1 (HMGB-1) were
determined as measures for end organ damage.
Materials and Methods
Ethics Statement
Animal experiments were approved by the University of Illinois
Animal Care and Use Committee (Chicago, IL, USA). Experi-
ments were performed following the guidelines from the Associ-
ation for Assessment and Accreditation of Laboratory Animal
Care. C57BL/6 mice were closely monitored before and during
the experiments. Mice received buprenorphine (0.1 mg/kg
subcutaneously) immediately after surgery and as needed there-
after for analgesia. Severely moribund animals were euthanized.
Animals
Eight to 12 week old male C57BL/6 mice (Charles River
Laboratories, Chicago, IL, USA) were used for experiments.
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Anesthesia and Sepsis Induction by Cecal Ligation and
Puncture
Cecal ligation and puncture (CLP) was carried out under
ketamine/xylazine anesthesia as described previously [4]. Briefly,
the distal 20% (below the ileocecal valve, about 1 cm from the tip)
of the cecum was ligated with a 6-0 suture. The cecum was
punctured through and through four times with a 20G needle.
The experiments were part of a series and the same CLP group
was used as in recent work due to ethical considerations [4]. In
CLP animals, saline was infused at 20 mL/kg/h (N=12). For
HFIP conditioning (N= 12), saline (20 mL/kg/h) containing
HFIP was administered through the right external jugular vein
for 30 min, immediately after CLP induction under ketamine/
xylazine anesthesia (0.015 or 0.04 mg HFIP/g body weight). The
animals were closely monitored and the depth and duration of
anesthesia was comparable for all groups. HFIP doses were based
on in vitro results and further reduced after observing lethal effects
in (severely compromised) CLP animals. The dose of 0.015 mg/g
is well below the reported LD50 value in (healthy) mice (0.18 mg
HFIP intravenous per g BW as reported by U.S. Army Armament
Research & Development Command, Chemical Systems Labora-
tory, NIOSH Exchange Chemicals. Vol. NX#03623).
For postconditioning experiments 24 hours after CLP induc-
tion, mice were anesthetized using ketamine (100 mg/kg, no
xylazine) for the intravenous administration of HFIP. In the
0.015 mg HFIP/g group 100% mortality was observed within
48 hrs (N= 8). Therefore, similarly to the sevoflurane experiments
in the previous study [4], a reduced dose of 0.0075 mg HFIP/g
was administered at the 24 hours time point.
Survival Study
For survival studies, animals were observed for up to 7 days at
,8 hrs intervals.
Blood Analysis 24 hours after Sepsis Induction
In additional experiments mice were harvested 24 hours after
CLP-induction (N= 6 per group). Blood samples were analyzed to
assess organ damage markers (Hitachi 916 chemistry analyzer,
Roche Diagnostics, Laval, Quebec, Canada). Inflammatory
mediators such as interleukin-6 (IL-6), monocyte chemoattractant
protein-1 (MCP-1) (both from BD Biosciences San Diego, CA) as
well as HMGB-1 (IBL International; Hamburg, Germany) were
measured following the manufacturer’s protocol.
Statistical Analysis
Survival data was analyzed using Bonferroni corrected log rank
tests in Origin (Kaplan Meier Survival Analysis, OriginLAB,
Northampton, MA, USA). Markers for organ function for treated
and untreated groups were compared using Mann-Whitney U
tests (two-tailed) and Bonferroni correction for multiple compar-
isons. Because of heteroscedasticity, rank transformation was
performed before the inflammatory mediator data set was
analyzed using linear regression analysis (inflammatory mediator
expression as dependent variable, affiliations to the respective
treatment group were coded as independent, dummy-coded
variables). P-values #0.05 were considered statistically significant.
Results and Discussion
In a murine CLP sepsis model we found that intravenous
administration of water-soluble HFIP showed markedly improved
overall 7-day survival (77%) compared to the CLP group (17%)
when administered in saline at a dose of 0.015 mg/g immediately
after CLP surgery (p = 0.037, N= 12) (Figure 1). SHAM-
operated mice tolerated HFIP doses of at least 0.08 mg/g.
However, in animals undergoing CLP procedure the administra-
tion of doses $0.04 mg/g HFIP was associated with a mortality of
100% by day 2. The measurement of biochemical parameters in
plasma 24 hours after CLP-induction revealed that HFIP
administration significantly attenuated CLP-induced organ injury
(Figure 2). Increased levels of blood urea nitrogen (BUN,
p= 0.010), alanine aminotransferase (ALT, p= 0.037) and aspar-
tate aminotransferase (AST, p= 0.001) but not of alkaline
phosphatase (ALP), were found in the CLP group compared to
SHAM animals 24 hours after induction of sepsis. In CLP+HFIP
group, mean ALT, AST and BUN levels were comparable to the
SHAM group, suggesting that HFIP significantly attenuated CLP-
induced organ injury. Plasma HMGB-1, representing a late phase
proinflammatory mediator in the pathogenesis of sepsis [6,7] was
upregulated fivefold in the CLP group at the 24 hours time point
compared to SHAM animals (p = 0.005, R2= 0.349). In CLP mice
that received HFIP plasma HMGB-1 levels were significantly
lower and not different from those in SHAM animals (p = 0.81,
R2= 0.349). No significant differences were found neither in
plasma levels of early inflammatory mediators (IL-6 and MCP-1)
nor in bacterial counts among the different groups. When HFIP
was administered 24 hours after sepsis induction (late post-
conditioning), no statistically significant differences in overall
survival were observed for both doses (0.015 mg/g and
0.0075 mg/g). At the 24 hours time point, mice showed
pronounced symptoms of sepsis and the ketamine anesthesia
required for catheter placement might have additionally compro-
mised the outcome in the late postconditioning group.
In summary, intravenous administration of the primary
sevoflurane metabolite HFIP provides significant protection
against severe septic peritonitis in a murine model. HFIP not
only decreases levels of surrogate markers, but also improves
outcome in the present animal model of experimental sepsis.
Underlying mechanisms of protection in septic peritonitis
remain to be investigated for both volatile anesthetics and HFIP.
HMGB-1 has recently been identified as a systemic marker with
prognostic impact that is released by necrotic and severely stressed
cells and functions as a late inflammatory mediator peaking
Figure 1. Survival analysis. Seven day survival of CLP mice, CLP mice
receiving HFIP immediately after CLP induction (CLP+HFIP, N= 12) (CLP
vs. CLP+HFIP, p = 0.037) and CLP animals receiving HFIP 24 hours after
sepsis induction (CLP+HFIP postcond., 24 h, N = 12) (CLP vs. CLP+HFIP
postcond., 24 h, ns) CLP: cecal ligation and puncture. HFIP: hexafluor-
oisopropanol. ns: non –significant.
doi:10.1371/journal.pone.0072057.g001
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considerably later than e.g. IL-6 or tumor necrosis factor (TNFa)
[7,8] and the observed protection is possibly mediated through
attenuated secretion of HMGB-1. This in good agreement with
previous studies which found significant protection against lethal
endotoxemia, sepsis, and LPS-induced acute lung injury, with
rodents being protected from development of organ damage and
failure through decreased extracellular levels of (free) HMGB-1
achieved by e.g. passive immunization, even when the HMGB-1
antibody administration was delayed [8,9]. In contrast to the
antagonization of early cytokines such as TNFa, therapeutic
neutralization of HMGB-1 has shown encouraging results in
experimental models of arthritis and sepsis, and may thus be a key
determinant for the rescue of septic animals [8,10].
Conclusion
In conclusion, the present study shows beneficial effects on
survival using a primary sevoflurane metabolite, HFIP, in a sepsis
model currently considered as the gold standard in experimental
sepsis. This is the first experimental study demonstrating a survival
benefit by administration of a volatile anesthetics metabolite. In
contrast to volatile anesthetics the metabolite is water-soluble and
intravenously injectable, which greatly extends the spectrum of
possible future applications to non-theater environments [4]. As
the intravascular application of volatile anesthetics is potentially
lethal and requires complex formulation [11], structure-similar
water-soluble compounds have the potential to overcome these
limitations. Validation in other animal models and insight into the
mechanism of action is now required before the actual therapeutic
relevance can be appreciated.
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Figure 2. Organ damage and Inflammation. Plasma levels of organ damage markers (blood urea nitrogen (BUN), alanine aminotransferase (ALT)
and aspartate aminotransferase (AST)) (A) and inflammatory mediators (interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1) and high
mobility group box protein-1 (HMGB-1)) (B) for the experimental groups (N= 6) 24 hours after sepsis induction. CLP: cecal ligation and puncture. HFIP:
hexafluoroisopropanol. IL-6: * denotes p,0.05 compared to SHAM.
doi:10.1371/journal.pone.0072057.g002
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